Terms: = Kidney tumors AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
82 results:
1. Cobimetinib Plus Vemurafenib in Patients With Solid tumors With
Meric-Bernstam F; Rothe M; Mangat PK; Garrett-Mayer E; Gutierrez R; Ahn ER; Cannon TL; Powell S; Krauss JC; Reynolds CM; von Mehren M; Behl D; Calfa CJ; Duvivier HL; Kaplan HG; Livingston MB; Sharma MR; Urba WJ; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300385. PubMed ID: 38096472
[TBL] [Abstract] [Full Text] [Related]
2. Management of Brain Metastases: A Review of Novel Therapies.
Bellur S; Khosla AA; Ozair A; Kotecha R; McDermott MW; Ahluwalia MS
Semin Neurol; 2023 Dec; 43(6):845-858. PubMed ID: 38011864
[TBL] [Abstract] [Full Text] [Related]
3. Case Report: Malignant melanoma in a patient with Crohn's disease treated with ustekinumab.
Axiaris G; Ioannou A; Papoutsaki M; Marinos L; Liontos M; Michopoulos S; Zampeli E
F1000Res; 2022; 11():424. PubMed ID: 37867623
[TBL] [Abstract] [Full Text] [Related]
4. Combined braf, MEK, and heat-shock protein 90 inhibition in advanced braf V600-mutant melanoma.
Eroglu Z; Chen YA; Smalley I; Li J; Markowitz JK; Brohl AS; Tetteh L; Taylor H; Sondak VK; Khushalani NI; Smalley KSM
Cancer; 2024 Jan; 130(2):232-243. PubMed ID: 37776537
[TBL] [Abstract] [Full Text] [Related]
5. SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in kidney Cancer.
Zhou X; Sekino Y; Li HT; Fu G; Yang Z; Zhao S; Gujar H; Zu X; Weisenberger DJ; Gill IS; Tulpule V; D'souza A; Quinn DI; Han B; Liang G
Cancer Res; 2023 Nov; 83(22):3813-3826. PubMed ID: 37695044
[TBL] [Abstract] [Full Text] [Related]
6. Case report of a patient with Erdheim-Chester disease presenting with neuro-endocrine symptoms and negative for braf mutation.
Lu L; Zhou J; Yan X; Jin R; Deng S; Lu W; Chen D
Medicine (Baltimore); 2023 May; 102(20):e33846. PubMed ID: 37335698
[TBL] [Abstract] [Full Text] [Related]
7. Identification of braf, CCND1, and MYC mutations in a patient with multiple primary malignant tumors: a case report and review of the literature.
Liu Z; Jin C; Zhang Y; Jiang Y; Wang J; Zheng L
World J Surg Oncol; 2023 May; 21(1):158. PubMed ID: 37221610
[TBL] [Abstract] [Full Text] [Related]
8. Incidence of urological cancers in neurological patients: a review of the literature from the EAU Young Academic Urologist Functional Group.
Cancrini F; Osman N; Doizi S; Guillot-Tantay C; Hüsch T; Illiano E; Tutolo M; Tienza A; Culha MG; Vale L; Raison N; Herve F; Grande P; Roupret M; Phé V
Minerva Urol Nephrol; 2023 Apr; 75(2):163-171. PubMed ID: 36999836
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract] [Full Text] [Related]
10. A retrospective single-centered, comprehensive targeted genetic sequencing analysis of prognostic survival using tissues from Korean patients with metastatic renal cell carcinoma after targeted therapy.
Kim SH; Park J; Park WS; Hong D; Chung J
Investig Clin Urol; 2022 Nov; 63(6):602-611. PubMed ID: 36347549
[TBL] [Abstract] [Full Text] [Related]
11. Machine learning-based prediction model for late recurrence after surgery in patients with renal cell carcinoma.
Kim HM; Byun SS; Kim JK; Jeong CW; Kwak C; Hwang EC; Kang SH; Chung J; Kim YJ; Ha YS; Hong SH
BMC Med Inform Decis Mak; 2022 Sep; 22(1):241. PubMed ID: 36100881
[TBL] [Abstract] [Full Text] [Related]
12. Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.
Shiraishi Y; Kishimoto J; Shimose T; Toi Y; Sugawara S; Okamoto I
BMC Cancer; 2022 Sep; 22(1):964. PubMed ID: 36076179
[TBL] [Abstract] [Full Text] [Related]
13. Truth or dare: switching braf/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.
De Ryck L; Delanghe S; Jacobs C; Fadaei S; Brochez L; Saerens M
Acta Clin Belg; 2023 Jun; 78(3):215-222. PubMed ID: 35996969
[TBL] [Abstract] [Full Text] [Related]
14. Novel GLCCI1-braf fusion drives kinase signaling in a case of pheochromocytomatosis.
Green BL; Grant RRC; Richie CT; Chatterjee B; Sampaio De Melo M; Barr FG; Pacak K; Agarwal SK; Nilubol N
Eur J Endocrinol; 2022 Jul; 187(1):185-196. PubMed ID: 35861986
[TBL] [Abstract] [Full Text] [Related]
15. Young age is associated with decreased recurrence for renal cell carcinoma.
Liu F; Davaro F; Wong R; Siddiqui S; Hamilton Z
Can J Urol; 2022 Jun; 29(3):11142-11149. PubMed ID: 35691035
[TBL] [Abstract] [Full Text] [Related]
16. Novel Therapeutics for Advanced Differentiated Thyroid Cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract] [Full Text] [Related]
17. Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083
[TBL] [Abstract] [Full Text] [Related]
18. T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages.
Torres GM; Yang H; Park C; Spezza PA; Khatwani N; Bhandari R; Liby KT; Pioli PA
Front Immunol; 2022; 13():768753. PubMed ID: 35265066
[TBL] [Abstract] [Full Text] [Related]
19. Metanephric adenoma: molecular study and review of the literature.
Rodríguez-Zarco E; Machuca-Aguado J; Macías-García L; Vallejo-Benítez A; Ríos-Martín JJ
Oncotarget; 2022; 13():387-392. PubMed ID: 35198098
[TBL] [Abstract] [Full Text] [Related]
20. Dabrafenib- and trametinib-associated glomerular toxicity: A case report.
Jo E; Rhee H
Medicine (Baltimore); 2022 Jan; 101(1):e28485. PubMed ID: 35029901
[TBL] [Abstract] [Full Text] [Related]
[Next]
